Molecular Partners AG
SIX:MOLN

Watchlist Manager

Molecular Partners AG

SIX:MOLN

Watchlist

Dividends

Price: 5.2 CHF 1.96% Market Closed

Market Cap: 191.6m CHF

Have any thoughts about
Molecular Partners AG?

Write Note

Write Note Create Alert Ask AI

Add Note Why Create Notes?

Capture your thoughts

Note Buy Sell Hold Pass

US	Johnson & Johnson NYSE:JNJ	Pharmaceuticals
US	Estee Lauder Companies Inc NYSE:EL	Consumer products
US	Exxon Mobil Corp NYSE:XOM	Energy
US	Church & Dwight Co Inc NYSE:CHD	Consumer products
US	Pfizer Inc NYSE:PFE	Pharmaceuticals
US	American Express Co NYSE:AXP	Financial Services
US	Nike Inc NYSE:NKE	Textiles, Apparel & Luxury Goods
US	Visa Inc NYSE:V	Technology
CN	Alibaba Group Holding Ltd NYSE:BABA	Retail
US	3M Co NYSE:MMM	Industrial Conglomerates
US	JPMorgan Chase & Co NYSE:JPM	Banking
US	Coca-Cola Co NYSE:KO	Beverages
US	Target Corp NYSE:TGT	Retail
US	Walt Disney Co NYSE:DIS	Media
US	Mueller Industries Inc NYSE:MLI	Machinery
US	PayPal Holdings Inc NASDAQ:PYPL	Technology

Add Price Alert

Price Target:

Last Price: 5.2 CHF

We'll email you a reminder when the closing price reaches USD.

If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.

Peter Lynch

Track and Analyze Performance

Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.

Continuous Learning and Adaptation

Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.

Boost Decision Confidence

With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.

Why create notes?

Back

Delete Note

Do you really want to delete this note?
This action cannot be undone.

Remove price alert for reaching

Delete

Cancel

MOLN Alert

Molecular Partners AG

5.2

+0.1 (+1.96%)

52 Week Range	3.17 9.3
Price Target

We'll email you a reminder when the closing price reaches CHF.

Save Alert

Choose the stock you wish to monitor with a price alert.

	Johnson & Johnson NYSE:JNJ	US
	Estee Lauder Companies Inc NYSE:EL	US
	Exxon Mobil Corp NYSE:XOM	US
	Church & Dwight Co Inc NYSE:CHD	US
	Pfizer Inc NYSE:PFE	US
	American Express Co NYSE:AXP	US
	Nike Inc NYSE:NKE	US
	Visa Inc NYSE:V	US
	Alibaba Group Holding Ltd NYSE:BABA	CN
	3M Co NYSE:MMM	US
	JPMorgan Chase & Co NYSE:JPM	US
	Coca-Cola Co NYSE:KO	US
	Target Corp NYSE:TGT	US
	Walt Disney Co NYSE:DIS	US
	Mueller Industries Inc NYSE:MLI	US
	PayPal Holdings Inc NASDAQ:PYPL	US

Delete Alert

This alert will be permanently deleted.

Remove note

Delete

Cancel

Ask me anything about

Molecular Partners AG

What unique competitive advantages
does Molecular Partners AG hold over its rivals?

What risks and challenges
does Molecular Partners AG face in the near future?

Is it considered overvalued or undervalued
based on the latest financial data?

Provide an overview of the primary business activities
of Molecular Partners AG.

What unique competitive advantages
does Molecular Partners AG hold over its rivals?

What risks and challenges
does Molecular Partners AG face in the near future?

Summarize the latest earnings call
of Molecular Partners AG.

Is it considered overvalued or undervalued
based on the latest financial data?

Show all valuation multiples
for Molecular Partners AG.

Provide P/S
for Molecular Partners AG.

Provide P/E
for Molecular Partners AG.

Provide P/OCF
for Molecular Partners AG.

Provide P/FCFE
for Molecular Partners AG.

Provide P/B
for Molecular Partners AG.

Provide EV/S
for Molecular Partners AG.

Provide EV/GP
for Molecular Partners AG.

Provide EV/EBITDA
for Molecular Partners AG.

Provide EV/EBIT
for Molecular Partners AG.

Provide EV/OCF
for Molecular Partners AG.

Provide EV/FCFF
for Molecular Partners AG.

Provide EV/IC
for Molecular Partners AG.

Show me price targets
for Molecular Partners AG made by professional analysts.

What are the Revenue projections
for Molecular Partners AG?

How accurate were the past Revenue estimates
for Molecular Partners AG?

What are the Net Income projections
for Molecular Partners AG?

How accurate were the past Net Income estimates
for Molecular Partners AG?

What are the EPS projections
for Molecular Partners AG?

How accurate were the past EPS estimates
for Molecular Partners AG?

What are the EBIT projections
for Molecular Partners AG?

How accurate were the past EBIT estimates
for Molecular Partners AG?

Compare the revenue forecasts
for Molecular Partners AG with those of its competitors based on recent analyst estimates.

Compare the intrinsic valuations
of Molecular Partners AG and its key competitors using the latest financial data.

Compare historical revenue growth rates
of Molecular Partners AG against its competitors.

Analyze the profit margins
(gross, operating, and net) of Molecular Partners AG compared to its peers.

Compare the P/E ratios
of Molecular Partners AG against its peers.

Discuss the investment returns and shareholder value creation
comparing Molecular Partners AG with its peers.

Analyze the financial leverage
of Molecular Partners AG compared to its main competitors.

Show all profitability ratios
for Molecular Partners AG.

Provide ROE
for Molecular Partners AG.

Provide ROA
for Molecular Partners AG.

Provide ROIC
for Molecular Partners AG.

Provide ROCE
for Molecular Partners AG.

Provide Gross Margin
for Molecular Partners AG.

Provide Operating Margin
for Molecular Partners AG.

Provide Net Margin
for Molecular Partners AG.

Provide FCF Margin
for Molecular Partners AG.

Show all solvency ratios
for Molecular Partners AG.

Provide D/E Ratio
for Molecular Partners AG.

Provide D/A Ratio
for Molecular Partners AG.

Provide Interest Coverage Ratio
for Molecular Partners AG.

Provide Altman Z-Score Ratio
for Molecular Partners AG.

Provide Quick Ratio
for Molecular Partners AG.

Provide Current Ratio
for Molecular Partners AG.

Provide Cash Ratio
for Molecular Partners AG.

What is the historical Revenue growth
over the last 5 years for Molecular Partners AG?

What is the historical Net Income growth
over the last 5 years for Molecular Partners AG?

What is the current Free Cash Flow
of Molecular Partners AG?

Discuss the annual earnings per share (EPS)
trend over the past five years for Molecular Partners AG.

MOLN

Income Statement

Income from Continuing Operations

Molecular Partners AG
Income from Continuing Operations

Last Value

3-Years 3-Y CAGR

5-Years 5-Y CAGR

10-Years 10-Y CAGR

Quarterly

Annual

TTM

Adjust for Inflation

Molecular Partners AG
Income from Continuing Operations Peer Comparison

Comparables:

ADCT

ACIU

CRSP

BSLN

KURN

Competitive Income from Continuing Operations Analysis
Latest Figures & CAGR of Competitors

	Income from Continuing Operations	CAGR 3Y	CAGR 5Y	CAGR 10Y
Molecular Partners AG SIX:MOLN	Income from Continuing Operations -CHf69.1m	CAGR 3-Years 1%	CAGR 5-Years -13%	CAGR 10-Years N/A
ADC Therapeutics SA NYSE:ADCT	Income from Continuing Operations -$234.5m	CAGR 3-Years 2%	CAGR 5-Years -14%	CAGR 10-Years N/A
AC Immune SA NASDAQ:ACIU	Income from Continuing Operations -CHf60.5m	CAGR 3-Years 7%	CAGR 5-Years N/A	CAGR 10-Years N/A
CRISPR Therapeutics AG NASDAQ:CRSP	Income from Continuing Operations -$239.6m	CAGR 3-Years N/A	CAGR 5-Years -84%	CAGR 10-Years N/A
Basilea Pharmaceutica AG SIX:BSLN	Income from Continuing Operations -CHf652k	CAGR 3-Years 76%	CAGR 5-Years 51%	CAGR 10-Years 33%
Kuros Biosciences AG SIX:KURN	Income from Continuing Operations -CHf8.9m	CAGR 3-Years -15%	CAGR 5-Years 5%	CAGR 10-Years N/A

What is Molecular Partners AG's Income from Continuing Operations?

Income from Continuing Operations
-69.1m CHF

Based on the financial report for Jun 30, 2024, Molecular Partners AG's Income from Continuing Operations amounts to -69.1m CHF.

What is Molecular Partners AG's Income from Continuing Operations growth rate?

Income from Continuing Operations CAGR 5Y
-13%

Over the last year, the Income from Continuing Operations growth was 23%. The average annual Income from Continuing Operations growth rates for Molecular Partners AG have been 1% over the past three years , -13% over the past five years .

Molecular Partners AG
SIX:MOLN

Molecular Partners AG
Income from Continuing Operations

Molecular Partners AG
Income from Continuing Operations Peer Comparison

Competitive Income from Continuing Operations Analysis
Latest Figures & CAGR of Competitors

See Also

What is Molecular Partners AG's Income from Continuing Operations?

Income from Continuing Operations
-69.1m CHF

What is Molecular Partners AG's Income from Continuing Operations growth rate?

Income from Continuing Operations CAGR 5Y
-13%

Company

Help

Tools

Stocks

Molecular Partners AG SIX:MOLN

Molecular Partners AG Income from Continuing Operations

Molecular Partners AG Income from Continuing Operations Peer Comparison

Competitive Income from Continuing Operations Analysis Latest Figures & CAGR of Competitors

See Also

What is Molecular Partners AG's Income from Continuing Operations? Income from Continuing Operations -69.1m CHF

What is Molecular Partners AG's Income from Continuing Operations growth rate? Income from Continuing Operations CAGR 5Y -13%

Company

Help

Tools

Stocks

Molecular Partners AG
SIX:MOLN

Molecular Partners AG
Income from Continuing Operations

Molecular Partners AG
Income from Continuing Operations Peer Comparison

Competitive Income from Continuing Operations Analysis
Latest Figures & CAGR of Competitors

What is Molecular Partners AG's Income from Continuing Operations?

Income from Continuing Operations
-69.1m CHF

What is Molecular Partners AG's Income from Continuing Operations growth rate?

Income from Continuing Operations CAGR 5Y
-13%